Literature DB >> 30878300

A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

Jeffrey Landercasper1, Luis D Ramirez2, Andrew J Borgert2, Humera F Ahmad2, Benjamin M Parsons3, Leah L Dietrich3, Jared H Linebarger3.   

Abstract

BACKGROUND: Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectomy versus mastectomy in the National Cancer Database (NCDB). PATIENTS AND METHODS: A retrospective cohort of patients with stage I-III breast cancer in the NCDB (2004-2013) was identified. Propensity score matching (PSM), Kaplan-Meier, and multivariate Cox proportional hazards models were used to examine OS by type of surgery.
RESULTS: Of 845,136 patients, 464,052 (54.9%) underwent lumpectomy and 381,084 (45.1%) underwent mastectomy. After PSM, the hazard ratio (HR) and confidence interval (CI) for OS in all patients comparing lumpectomy with mastectomy was 1.02 (CI, 1.00-1.04; P = .002). In patients with stage I, II, and III, they were HR 1.27 (CI, 1.23-1.36; P < .001), HR 0.98 (CI, 0.95-1.01; P = .21), and HR 0.83 (CI, 0.80-0.86; P < .001), respectively. In subgroup analyses of all patients by estrogen receptor (ER) status, they were HR 1.05 (CI, 1.03-1.07; P < .001) and HR 1.00 (CI, 0.96-1.03; P = .65) in ER+ and ER- patients.
CONCLUSION: In our primary model of all stage I-III matched patients, using the most recent NCDB data and the largest observational sample size to date, the OS after mastectomy was not inferior to lumpectomy. This finding can be reassuring to patients and providers. In subgroup analyses, the association between type of surgery and OS differed by cancer stage and hormone receptor status.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast-conserving surgery; Cancer outcomes; Mastectomy; Overall survival; Type of surgery

Mesh:

Year:  2019        PMID: 30878300     DOI: 10.1016/j.clbc.2019.02.006

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  4 in total

Review 1.  Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients.

Authors:  Gabriel De la Cruz Ku; Manish Karamchandani; Diego Chambergo-Michilot; Alexis R Narvaez-Rojas; Michael Jonczyk; Fortunato S Príncipe-Meneses; David Posawatz; Salvatore Nardello; Abhishek Chatterjee
Journal:  Ann Surg Oncol       Date:  2022-07-25       Impact factor: 4.339

Review 2.  Signaling pathways governing breast cancer stem cells behavior.

Authors:  Kai Song; Maryam Farzaneh
Journal:  Stem Cell Res Ther       Date:  2021-04-16       Impact factor: 6.832

3.  Refusal of cancer-directed surgery in male breast cancer.

Authors:  Shipei Wang; Sichao Chen; Yihui Huang; Di Hu; Wen Zeng; Ling Zhou; Wei Zhou; Danyang Chen; Haifeng Feng; Wei Wei; Chao Zhang; Zeming Liu; Min Wang; Liang Guo
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

4.  Radiotherapy plays an important role in improving the survival outcome in patients with T1-2N1M0 breast cancer - a joint analysis of 4262 real world cases from two institutions.

Authors:  Guang-Yi Sun; Ge Wen; Yu-Jing Zhang; Yu Tang; Hao Jing; Jian-Yang Wang; Jiang-Hu Zhang; Yong Yang; Xu-Ran Zhao; Si-Ye Chen; Jing Jin; Yong-Wen Song; Yue-Ping Liu; Hui Fang; Hua Ren; Yuan Tang; Shu-Nan Qi; Ning Li; Bo Chen; Ning-Ning Lu; Shu-Lian Wang; Ye-Xiong Li
Journal:  BMC Cancer       Date:  2020-11-26       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.